With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

Fintel reports that on December 11, 2025, Stifel maintained coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...